Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 1, 1999, Pages 424-433

  Ekins, Sean ^a   Bravi, Gianpaolo ^a,b   Wikel, James H ^a   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 NITROPYRENE; BUPRENORPHINE; CLARITHROMYCIN; CYCLOSPORIN; CYCLOSPORIN G; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; DILTIAZEM; DOCETAXEL; ERYTHROMYCIN; FELODIPINE; HYDROCORTISONE; INDINAVIR; MESYLIC ACID; MIDAZOLAM; NIFEDIPINE; PACLITAXEL; QUINIDINE; RAPAMYCIN; RIFABUTIN; RITONAVIR; SAQUINAVIR; TACROLIMUS; TERFENADINE; TESTOSTERONE; TIRILAZAD; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINDESINE;

ARTICLE; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME SUBSTRATE; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LIGANDS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0032822383     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Abel SM and Back DJ (1993) Cortisol metabolism in vitro. III. Inhibition of microsomal 6β-hydroxylase and cytosolic 4-ene reductase. J Steroid Biochem Mol Biol 46:827-832.
2. Andersson T, MIners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA and Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521-530.
3. Baarnhielm C, Dahlback H and Skanberg I (1986) In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol 59:113-122.
4. Bravi G, Gancia E, Mascani P, Pegna M, Todeschini R and Zaliani A (1997) MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids. J Comp Aided Mol Des 11:79-92.
5. Domanski TL, Liu J, Harlow GR and Halpert JR (1998) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: Role in steroid hydroxylase activity and α-napthoflavone stimulation. Arch Biochem Biophys 350: 223-232.
6. Eiermann B, Engel G, Johansson I, Zanger UM and Bertilsson L (1997) The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 44:439-446.
7. Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, VandenBranden M, Wrighton SA and Wikel JH (1999) Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6. J Pharmacol Exp Ther 288:21-29.
8. Ekins S, Ring BJ, Binkley SN, Hall SD and Wrighton SA (1998a) Autoactivation and activation of cytochrome P450s. Int J Clin Pharmacol Ther 36:642-651.
9. Ekins S, VandenBranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV and Wrighton SA (1998b) Further characterization of the expression in liver and catalytic activity of CYP2B6 J Pharmacol Exp Ther 286:1253-1259.
10. Fabre G, Julian B, Saint-Aubert B, Joyeux H and Berger Y (1993) Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21:978-985.
11. Feierman DE and Lasker JM (1996) Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Drug Metab Dispos 24:932-939.
12. Ferenczy GG and Morris GM (1989) the active site of cytochrome P-450 nifedipine oxidase: A model-building study. J Mol Graphics 7:206-211.
13. Fitzsimmons ME and Collins JM (1996) Selective biotransformation of the HIV protease inhibitor saquinavir by human small intestinal cytochrome P450 3A4: Potential contribution to high first-pass metabolism. ISSX Proc 10:400.
14. Gentile DM, Tomlinson ES, Maggs JL, Park BK and Back DJ (1996) Dexamethasone metabolism by human liver in vitro: Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 277:105-112.
15. Ghosal A, Satoh H, Thomas PE, Bush E and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human P450. Drug Metab Dispos 24:940-947.
16. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman DJ (1986a) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
17. Guengerich FP, Muller-Enoch D and Blair IA (1986b) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287-295.
18. Haaz M-C, Rivory L, Riche C, Vernillet L and Robert J (1998) Metabolism of Irinotecan (CPT-11) by human hepatic microsmes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468-472.
19. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P4503A4. J Biol Chem 272:5396-5402.
20. He YA, He YQ, Szklarz GD and Halpert JR (1997) Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis. Biochemistry 36:8831-8839.
21. Iatsimiskaia E, Tiulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N and Koudriakova T (1997) Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme sytems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 61:554-662.
22. Iribarne C, Picart D, Dreano Y, Bail J-P and Berthou F (1997) Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 22:1953-1964.
23. Irshaid Y, Adedoyn A, Lotze M and Branch RA (1994) Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes. Drug Metab Dispos 22:161-164.
24. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C and Berthou F (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41: 1911-1919.
25. Jang GR and Benet LZ (1997) Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone. Drug Metab Dispos 25:1119-1122.
26. Jang GR, Wrighton SA and Benet LZ (1996) Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol 52:753-761.
27. Jones BC, Hawksworth G, Horne VA, Newlands A, Morsman J, Tute MS and Smith DA (1996a) Putative active site template model for cytochrome P4602C9 (tolbutamide hydroxylase). Drug Metab Dispos 24:260-266.
28. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ and Levy RH (1994) Human liver carbamazepine metabolism. Biochem Pharmacol 47:1969-1979.
29. Koley AP, Buters JTM, Robinson RC, Markowitz A and Friedman FK (1995) CO binding kinetics of human cytochrome P450 3A4.J Biol Chem 270:5014-5018.
30. Koley AP, Robinson RC, Markowitz A and Friedman FK (1997) Drug-drug interactions: Effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem Pharmacol 53:455-460.
31. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, RA P, Rettie AE and Gonzalez FJ (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate-models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
32. Koymans L, Vermeulen NPE, van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsen K, Meuldermans W and Donne-Op den Kelder GM (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211-219.
33. Kroemer HK, Echizen H, Heidemann H and Eichelbaum M (1992) Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 260:1052-1057.
34. Kronback T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 38:89-96.
35. Kubinyi H (1997) QSAR and 3D QSAR in drug design. Part 2: Applications and problems. Drug Discovery Today 2:538-546.
36. Kumar GI, Rodrigues AD, Buko AM and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor (ABT-538) in human liver microsomes. J Pharmacol Exp Toxicol 277:423-431.
37. Kumar GN, Walle UK and Walle T (1994) Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydroxylation. J Pharmacol Exp Ther 268:1160-1165.
38. Lewis DFV (1995) Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). Xenobiotica 25:333-366.
39. Lewis DFV, Eddershaw PJ, Goldfarb PS and Tarbit MH (1996) Molecular modelling of CYP3A4 from an alignment with CYP102: Identifcation of key interactions between putative active site residues and CYP3A- specific chemicals. Xenobiotica 10:1067-1086.
40. Lewis DFV and Lake BG (1996) Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: Rationalization of CYP1A substrate specificity in terms of active site amino acid residues. Xenobiotica 26:723-753.
41. Lewis DFV and Lake BG (1998) Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. Toxicology 125:31-44.
42. Lin JH, Chiba M, Balani SK, Chen I-W, Kwei GY-S, Vastag KJ and Nishime JA (1996) Species differences in the pharmacokinetics and the metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:1111-1120.
43. Machinist JM, Mayer MD, Shet MS, Ferrero JL and Rodrigues AD (1995) Identification of the human liver cytochrome P450 enzymes involved in the metabolism of Zileuton (ABT-077) and its N-dehdroxylated metabolite, Abbott-66193. Drug Metab Dispos 23:1163-1174.
44. Mancy A, Broto P, Dijols S, Dansette PM and Mansuy D (1995) The substrate binding site of human liver cytochrome P4502C9: An approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 34:10365-10375.
45. Marre F, Sanderink G-J, de Sousa G, Gaillard C, Martinet M and Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302.
46. Miranda CL, Reed RI, Guengerich FP and Buhler DR (1991) Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver. Carcinogenesis 12:515-519.
47. Nelsestuen GL and Martinez MB (1997) Steady state enzyme velocities that are independent of [enzyme]: An important bevavior in many membrane and particle-bound states. Biochemistry 36:9081-9086.
48. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
49. Pichard L, Domerergue J, Fourtanier G, Koch P, Schran HF and Maurel P (1996) Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochem Pharmacol 51:591-598.
50. Pichard L, Fabre I, Fabre G, Domergue J, Aubert BS, Mourad G and Maurel P (1990) Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
51. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH and Vyas KP (1997) In vitro metabolism of simvastatin in humans [SBT]: Identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191-1199.
52. Ring BJ, Parli CJ, George MC and Wrighton SA (1994) In vitro metabolism of zatosetron: Interspecies comparison and role of CYP. Drug Metab Dispos 22:352-357.
53. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS and Estabrook RW (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Drug Metab Dispos 23:765-775.
54. Rodrigues AD, Roberta EM, Mulford DJ, Yao Y and Ouellet D (1997) Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Drug Metab Dispos 25:623-630.
55. Sattler M, Guengerich FP, Yun C-H, Christains U and Sewing K-F (1992) Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753-761.
56. Schmider J, Greenblatt DJ, vin Moltke LL, Harmatz JS, Duan SX, Karsov D and Shader RI (1996) Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies. Pharmacology 52:125-134.
57. 5. Arch Biochem Biophys 348:107-115.
58. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
59. Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, Shimada T and Funae Y (1994) Metabolism of FK506, a potent immunosuppresive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 47:727-735.
60. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV and Korzekwa KR (1994) Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
61. Silvers KJ, Chazinski T, McManus ME, Bauer SL, Gonzalez FJ, Gelboin HV, Maurel P and Howard PC (1992) Cytochrome P-450 3A4 (nifedipine oxidase) is responsible for the oxidative metabolism of 1-nitropyrene in human liver microsomal samples. Cancer Res 52:6237-6243.
62. Smith DA, Ackland MJ and Jones BC (1997a) Properties of cytochrome P450 isoenzymes and their substrates. Part 1: Active site characteristics. Drug Discovery Today 2:406-414.
63. Smith DA, Ackland MJ and Jones BC (1997b) Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates. Drug Discovery Today 2:479-486.
64. Smith DA and Jones BC (1992) Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44:2089-2098.
65. Surapaneni SS, Clay MP, Spangle LA, Paschal JW and Lindstrom TD (1997) In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone. Drug Metab Dispos 25:1383-1388.
66. Sutton D, Butler AM, Nadin L and Murray M (1997) Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 282:294-300.
67. Szklarz GD and Halpert JR (1997) Molecular modeling of cytochrome P4503A4. J Comp Aided Mol Des 11:265-272.
68. Tateishi T, Soucek P, Caraco Y, Guengerich FP and Wood AJJ (1996) Colchicine biotransformation by human liver microsomes. Biochem Pharmacol 53:111-116.
69. Tomlinson ES, Lewis DFV, Maggs JL, Kroemer HK, Park BK and Back DJ (1997) In vitro metabolism of dexamethasone (DEX) in human liver and kidney: The involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem Pharmacol 54:605-611.
70. VandenBranden M, Ring BJ, Binkley SN and Wrighton SA (1996) Interaction of human liver cytochromes P460 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6:81-91.
71. Venkatkrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI and Greenblatt DJ (1998) Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol 50:265-274.
72. Wang RW, Newton DJ, Scheri TD and Lu AYH (1997) Human cytochrome P450 3A4-catalyzed testosterone 60-hydroxylation and erythromycin N-demethylation. Drug Metab Dispos 25:502-507.
73. Wienkers LC, Steenwyk RC, Sanders PE and Pearson PG (1996) Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther 277:982-990.
74. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
75. Zhang Y, Guo X, Lin ET and Benet LZ (1998) Overlapping substrate specificities of cytochrome P4503A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Dispos 26:360-366.
76. Zhao X-J, Yokoyama H, Chiba K, Wanwimolruk S and Ishizaki T (1996) Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther 279:1327-1334.
77. Zhou X-J, Zhou-Pan X-R, Gauthier T, Placidi M, Maurel P and Rahmani R (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem Pharmacol 45:853-861.
78. Zhou-Pan X-R, Seree E, Zhou X-J, Placidi M, Maurel P, Barra Y and Rahmani R (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 53:5121-5126.